RecruitingResistant Hypertension
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
Eligible age
22–80 yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
Sponsor: DeepQure Inc.
You may qualify if…
- ✓ Subjects are eligible to participate if all of the following criteria are met:
- ✓ 1. Aged ≥22 and ≤80 years old at time of enrollment (consent).
- ✓ 2. Diagnosed with resistant hypertension.
- ✓ 3. Office BP ≥140/90 mmHg at Screening Visit 1, and on at least 3 antihypertensive medications of different classes including a diuretic for at least 4 weeks prior to consent.
- ✓ 4. Daytime ABP ≥135/85 mmHg after a four (4)-week run-in period at Screening Visit 2.
- ✓ 5. Agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.
You may not qualify if…
- ✕ Subjects are not eligible to participate if any of the following criteria are met:
- ✕ 1. Has coverage diameter of renal artery less than 2 mm or greater than 11 mm.
- ✕ 2. Has one or more of the following conditions:
- ✕ 1. Unstable angina with stent implantation (percutaneous coronary intervention) within 3 months of enrolment.
- ✕ 2. Myocardial infarction within 3 months of enrollment.
- ✕ 3. Acute heart failure (New York Heart Association (NYHA) III-IV) within 3 months of enrollment
- ✕ 4. Cerebrovascular accident or transient ischemic attack within 3 months of enrollment.
- ✕ 5. Atrial fibrillation patients undergoing treatment and not in sinus rhythm. Notes: Patients who have received medical treatment, catheter or surgical treatment for atrial fibrillation and are in sinus rhythm are not excluded
Where it's recruiting
Source: ClinicalTrials.gov · NCT06526858 · last updated 2026-08-10